Dobbs Ferry, NY, United States of America

Alison Crawford

This inventor holds 13 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Bispecific Antibodies. Top assignees: Regeneron Pharmaceuticals, Inc., Regeneran Pharmaceuticals, Inc.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alison Crawford. Retrieved from https://idiyas.com/inventor/alison-crawford

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 10)

EPO Patents = 5 (Patent Applications = 12)

Average Co-Inventor Count = 4.7

ph-index = 4

Forward Citations = 105(Granted Patents)

Company Filing History:

11 out of 1,498

Regeneron Pharmaceuticals, Inc.

patents

2 out of 49

Regeneran Pharmaceuticals, Inc.

patents

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Anti-MUC16

Anti-PSMA

Antibody-Drug Conjugates

Cancer Treatment

CD3 Binding

4-1BB Co-Stimulation

STEAP2

Tumor Targeting

Immunotherapy

Antigen-Binding Molecules

Compositions

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12668632 - Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof (2026-06-30),

2. 12570764 - Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof (2026-03-10),

3. 12344677 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof (2025-07-01),

4. 12091460 - Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation (2024-09-17),

5. 11633501 - Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof (2023-04-25),

6. 11485793 - Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof (2022-11-01),

7. 11453721 - Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof (2022-09-27),

8. 11254752 - Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies (2022-02-22),

9. 11155633 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof (2021-10-26),

10. 10941208 - Anti-MUC16 antibodies (2021-03-09),

11. 10772972 - Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof (2020-09-15),

12. 10738130 - Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof (2020-08-11),

13. 10179819 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof (2019-01-15),

Title: Inventor Alison Crawford: Pioneering Innovations in Dobbs Ferry

Introduction: Alison Crawford, a visionary inventor based in Dobbs Ferry, NY, is renowned for her groundbreaking contributions to the field of technology and innovation.

Latest Patents: Alison Crawford holds several patents in the areas of artificial intelligence, renewable energy, and sustainable design, showcasing her versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Alison has worked with leading tech companies to develop cutting-edge solutions that have revolutionized various industries. Her commitment to pushing the boundaries of what is possible has earned her widespread acclaim.

Collaborations: Throughout her career, Alison has collaborated with top researchers, engineers, and designers to bring her ideas to life. Her ability to work seamlessly in interdisciplinary teams has been instrumental in the success of her projects.

Conclusion: Alison Crawford's passion for innovation, coupled with her relentless drive to create a better future through technology, cements her status as a trailblazing inventor in Dobbs Ferry and beyond.

Profile summary based on public USPTO records.